Scientists at the Instituto Gulbenkian de Ciкncia (IGC), in Portugal, have shown that Malaria eradication in Africa is sustainable, and any re-emergence of malaria in industrialized nations is highly unlikely. Working with colleagues in Kenya, the IGC researchers created a mathematical model of malaria transmission throughout sub-Saharan Africa, published in this week’s PLoS ONE.

A new drug that will soon enter clinical trials for treatment of malaria also appears to be 10 times more effective than the key medicine in the current gold-standard treatment for toxoplasmosis, a disease caused by a related parasite that infects nearly one-third of all humans—more than two billion people worldwide.

Could a simple vitamin A and zinc supplement help protect young children from malaria" A randomized double blind trial reported in the open access publication, Nutrition Journal, would suggest the answer is yes.

A small clinical trial conducted by an international team of researchers in Mali has found that a candidate malaria vaccine was safe and elicited strong immune responses in the 40 Malian adults who received it.

University of Navarra PhD in chemistry researcher, Esther Vicente, has discovered new compounds active for treating tuberculosis and malaria.

The current dosage of drugs used in treating malaria may be helping the parasites become resistant to the drugs faster, without improving the long-term outcome in patients.

Using insect repellent in addition to insecticide treated bednets (ITNs) has been shown to provide greater protection against malaria in areas where mosquitoes feed in the early evening.

How are physicists helping an effort to eradicate malaria, the mosquito-borne disease that kills more than one million people every year" Researchers at the National Institute of Standards and Technology (NIST) used their expertise in radiation science to help a young company create weakened, harmless versions of the malaria-causing parasite.

The first study to test GlaxoSmithKline's (GSK) investigational RTS,S/AS02 malaria vaccine in African infants serves as the first proof of concept in this population that the vaccine has a promising safety and tolerability profile and reduces malaria parasite infection and clinical illness due to malaria, according to a paper published today online in The Lancet.

Researchers at the Swedish medical university Karolinska Institutet (KI) and the Swedish Institute for Infectious Disease Control (SMI) have identified the biochemical mechanism behind the adhesive protein that give rise to particularly serious malaria in children.

Scientists in the United States have taken an important step in the effort to end malaria. At Johns Hopkins Malaria Research Institute, scholars recently identified a sugar in mosquitoes that helps explain, for the first time, the mechanism of the malaria parasite invasion.

A global network to monitor drug resistance and guide malaria treatment and prevention policies is being launched.